Tools
Tools
Tembo, G., Mayuni, M., Kamng'ona, R., Chimgoneko, L., Chiwala, G., Sichone, S., Galafa, B., Thole, F., Mkandawire, C., Chirwa, A.E., Nsomba, E., Nkhoma, V., Ngoliwa, C., Toto, N., Makhaza, L., Muyaya, A., Kudowa, E., Henrion, Marc, Dula, D., Morton, Ben 
ORCID: https://orcid.org/0000-0002-6164-2854, Chikaonda, T., Gordon, Stephen ORCID: https://orcid.org/0000-0001-6576-1116 and Jambo, Kondwani ORCID: https://orcid.org/0000-0002-3195-2210
(2024)
'Poor association between 13-valent pneumococcal conjugate vaccine-induced serum and mucosal antibody responses with experimental Streptococcus pneumoniae serotype 6B colonisation'. Vaccine, Vol 42, Issue 12, pp. 2975-2982.
|
Text
1-s2.0-S0264410X24003608-main.pdf - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (3MB) | Preview |
Abstract
Background
Pneumococcal carriage is the primary reservoir for transmission and a prerequisite for invasive pneumococcal disease. Pneumococcal Conjugate Vaccine 13 (PCV13) showed a 62% efficacy in protection against experimental Streptococcus pneumoniae serotype 6B (Spn6B) carriage in a controlled human infection model (CHIM) of healthy Malawian adults. We, therefore, measured humoral responses to experimental challenge and PCV-13 vaccination and determined the association with protection against pneumococcal carriage.
Methods
We vaccinated 204 young, healthy Malawian adults with PCV13 or placebo and nasally inoculated them with Spn6B at least four weeks post-vaccination to establish carriage. We collected peripheral blood and nasal lining fluid at baseline, 4 weeks post-vaccination (7 days pre-inoculation), 2, 7, 14 and > 1 year post-inoculation. We measured the concentration of anti-serotype 6B Capsular Polysaccharide (CPS) Immunoglobulin G (IgG) and IgA antibodies in serum and nasal lining fluid using the World Health Organization (WHO) standardised enzyme-linked immunosorbent assay (ELISA).
Results
PCV13-vaccinated adults had higher serum IgG and nasal IgG/IgA anti-Spn6B CPS-specific binding antibodies than placebo recipients 4 to 6 weeks post-vaccination, which persisted for at least a year after vaccination. Nasal challenge with Spn6B did not significantly alter serum or nasal anti-CPS IgG binding antibody titers with or without experimental pneumococcal carriage. Pre-challenge titers of PCV13-induced serum IgG and nasal IgG/IgA anti-Spn6B CPS binding antibodies did not significantly differ between those that got experimentally colonised by Spn6B compared to those that did not.
Conclusion
This study demonstrates that despite high PCV13 efficacy against experimental Spn6B carriage in young, healthy Malawian adults, robust vaccine-induced systemic and mucosal anti-Spn6B CPS binding antibodies did not directly relate to protection.
Statistics
Actions (login required)
 |
Edit Item |